Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential

Summary

A method is described by which the time-course of thrombin generation in plasma can be obtained from a continuous optical density recording of p-nitroaniline (pNA) production in a 2:3 diluted plasma. A chromogenic substrate, methylmalonyl-methylanalyl-arginyl-pNA (SQ68), is used that is specifically split by thrombin but at a low rate. The thrombin that appears and disappears in the plasma does not split more than 5% of the substrate added, so the rate of substrate conversion is in good approximation proportional to the amidolytic activity in the plasma over the entire period of thrombin generation. The course of the enzyme concentration can be calculated from the amidolytic activity curve. It is shown that the thrombin generation curves obtained in this way are essentially identical to those obtained via the classical subsampling method.

The presence of SQ 68 influences the amount of free thrombin that appears in plasma because it competitively inhibits the inactivation of thrombin by AT III and α₂ macroglobulin. The inhibition of the thrombin peak by heparin, relative to an uninhibited control, remains unaltered by the presence of the substrate.

From the course of thrombin activity and the prevailing decay constants, the course of prothrombin conversion velocity can be calculated. Prothrombin conversion was seen to be inhibited at high (>500 μM) substrate concentrations only, and experimental conditions are found under which the inhibition of the clotting process by the substrate is negligible

The amidolytic activity is the sum of the activities of free thrombin and of the α₂ macroglobulin-thrombin complex formed. Via a mathematical procedure the amount of SQ 68 that has been split by thrombin alone and not by the a₂ macroglobulin-thrombin complex, can be derived from the course of the optical density.

The total amount of SQ 68 eventually split by thrombin alone is proportional to the surface under the thrombin generation curve, i. e. to the time-integral of free thrombin. This value, that we call the thrombin potential (TP), directly indicates how much of any physiological substrate can potentially be split by the thrombin being generated in the plasma.

• References

• 1 Hemker HC, Willems GM, Béguin S. A Computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
• 2 Béguin S, Kessels H, Dol F, Hemker HC. The consumption of antithrombin III during coagulation, its consequences for the calculation of the prothrombinase activity and the standardisation of heparin activity. Thromb Haemostas 1992; 68: 136-142
• 3 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemostas 1988; 60: 457-462
• 4 Josso F, Prou-Wartelle O. Exploration de l’hemostase. In Techniques en hematologie. Alagille D. et al (eds) Paris: Flammarion; 1972: 101-108
• 5 Pletcher CH, Nelsestuen GL. The rate determining step of the heparin-catalysed antithrombin/thrombin reaction is independent of thrombin. J Biol Chem 1982; 257: 5342-5345
• 6 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem 1980; 185: 647-658
• 7 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 8 Odegaard OR, Lee M. On the use of chromogenic substrates for studies of coagulation inhibitors. Haemostasis 1978; 7: 121-126
• 9 Griffith MJ. Measurement of the heparin enhanced-antithrombin III/ thrombin reaction rate in the presence of synthetic substrate. Thromb Res 1982; 25: 245-253
• 10 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1984; 52: 655-709
• 11 Biggs R, MacFarlane RG. Human Blood Coagulation and its disorders. Oxford: Blackwell Scientific Publications; 1953
• 12 Hemker HC, Wielders S, Béguin S. The thrombin potential, a Parameter to assess the effect of antithrombotic drugs on thrombin generation. In: Fraxiparine. Bounameaux H, Samama M, ten Cate JW. (eds) Stuttgart, New York: Schattauer; 1990: 89-101
• 13 Seegers W. Prothrombin. Cambridge, MA: Harvard University Press; 1962
• 14 Pekelharing CA. Über die Gerinnung des Blutes. Dtsch Med Wochenschr 1892; 18: 1133-1136
• 15 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma its inhibition by heparin. Thromb Haemostas 1989; 61: 25-29
• 16 Chesebro JH, Zoldhelyi P, Badimon L, Fuster V. Role of thrombin in arterial thrombosis; Implications for therapy. Thromb Haemostas 1991; 66: 1-5
• 17 Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood 1991; 78: 423-434
• 18 Hemker HC. Interaction of clotting factors. In: Handbook of Haemophilia. Brinkhous KM, Hemker HC. (eds) Amsterdam: Exerpta Medica; 1975
• 19 Hemker HC. Thrombin generation, an essential Step in haemostasis and thrombosis. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds) London: Churchill Livingstone 3.. in press